Stock 2196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Market Closed - Hong Kong S.E.
Other stock markets
 04:09:05 2024-06-07 EDT 		5-day change 1st Jan Change
14.08 HKD +2.18% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +15.03% -17.18%
06-07 Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3% MT
06-03 Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7% MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Chinese Regulator Accepts Fosun Pharma Unit's Drug Registration Application for Luvometinib Tablets; Shares Up 3%
MT
Shanghai Fosun Pharmaceutical Buys Remaining 49% Stake in Nursing Home; Shares Rise 7%
MT
China Approves Clinical Trials For Breast Cancer Drugs
MT
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets
MT
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug
MT
Fosun Pharma's Q1 Profit Slumps 38%
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.
CI
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates
MT
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
CI
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug
MT
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan
MT
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs
MT
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug
MT
Shanghai Fosun Pharmaceutical Co., Ltd. Enter into Mutual Supply Framework Agreement with Fosun International Limited
CI
Chinese Drug Regulator Accepts Fosun Pharma Subsidiary's Application for Diet Supplement
MT
Fosun Pharmaceutical's Unit Gets Greenlight to Test Cancer Drug in US, China
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 2196 Stock
  5. News Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. Highlights